216
Participants
Start Date
May 21, 2019
Primary Completion Date
June 5, 2020
Study Completion Date
June 5, 2020
Tezepelumab (APFS)
Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
Tezepelumab (AI)
Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
Research Site, Savannah
Research Site, Tampa
Research Site, Hoover
Research Site, Cincinnati
Research Site, Omaha
Research Site, Edmond
Research Site, McKinney
Research Site, Dallas
Research Site, San Antonio
Research Site, San Antonio
Research Site, Gilbert
Research Site, Northridge
Research Site, Palm Desert
Research Site, Westminster
Research Site, Medford
Research Site, Northfield
Research Site, Calgary
Research Site, Ajax
Research Site, Burlington
Research Site, Mississauga
Research Site, Ottawa
Research Site, Windsor
Research Site, Montreal
Research Site, Québec
Research Site, Québec
Research Site, Trois-Rivières
Research Site, Chūōku
Research Site, Fukuoka
Research Site, Bialystok
Research Site, Krakow
Research Site, Poznan
Research Site, Poznan
Research Site, Strzelce Opolskie
Research Site, Tarnów
Research Site, Wieluń
Research Site, Wroclaw
Lead Sponsor
Collaborators (1)
Amgen
INDUSTRY
AstraZeneca
INDUSTRY